Personalis, Inc. (PSNL)
Personalis, Inc. is a cancer genomics company providing sequencing and data analysis services to support cancer therapy development and genetic research. Their NeXT platform offers comprehensive tumor and immune microenvironment profiling from limited samples.
Company Overview
Personalis, Inc. pioneers cancer genomics with its NeXT platform, offering comprehensive tumor and immune profiling to biopharmaceutical companies, universities, and research institutions, driving personalized cancer therapy development and securing a leading position in the rapidly evolving precision medicine market.
Investment Thesis
Personalis presents a compelling investment opportunity due to its leading position in the rapidly growing cancer genomics market. The company's NeXT platform offers a comprehensive solution for tumor and immune profiling, driving significant value for biopharmaceutical companies in developing personalized cancer therapies. With a market capitalization of $0.72 billion, Personalis is poised for growth as the demand for advanced genomic sequencing and data analysis increases. Key value drivers include expanding partnerships with pharmaceutical companies and research institutions, increasing adoption of the NeXT platform, and the potential for new product launches. The company's negative P/E ratio of -9.67 reflects its investment in growth and innovation, while a gross margin of 26.7% indicates potential for improved profitability as the company scales its operations. The company's partnerships with Mayo Clinic and other institutions further validate its technology and market position.
Key Highlights
- Market capitalization of $0.72 billion reflects investor valuation of Personalis's potential in the cancer genomics market.
- Gross margin of 26.7% indicates the company's ability to generate revenue above direct costs, with potential for expansion.
- Partnerships with Mayo Clinic, MapKure, LLC, SpringWorks Therapeutics, Inc., and Moores Cancer Center validate the company's technology and market position.
- The NeXT platform provides comprehensive tumor and immune profiling, a key differentiator in the competitive landscape.
- 228 employees dedicated to advancing cancer genomics and personalized medicine.
Competitors
Strengths
- Comprehensive NeXT Platform for tumor and immune profiling.
- Strong partnerships with leading research institutions.
- Expertise in cancer genomics and data analysis.
- Proprietary technology for neoantigen prediction.
Weaknesses
- Negative profit margin (-106.9%) indicating profitability challenges.
- High beta (2.02) suggesting high volatility.
- Reliance on biopharmaceutical partnerships for revenue.
- Limited geographic diversification.
Catalysts
- Upcoming: Announcement of new partnerships with biopharmaceutical companies to integrate the NeXT platform into drug development pipelines.
- Ongoing: Increasing adoption of the NeXT Liquid Biopsy platform for cancer diagnosis and monitoring.
- Ongoing: Development and launch of new diagnostic tests based on genomic sequencing and data analysis capabilities.
- Ongoing: Expansion of geographic reach into new markets, particularly in Europe and Asia.
Risks
- Potential: Intense competition from established and emerging players in the cancer genomics market.
- Potential: Evolving regulatory landscape for genomic testing impacting market access and reimbursement.
- Potential: Technological advancements rendering existing technologies obsolete.
- Ongoing: Negative profit margin (-106.9%) indicating potential financial sustainability concerns.
- Ongoing: High beta (2.02) suggesting high stock price volatility.
Growth Opportunities
- Expanding Partnerships with Biopharmaceutical Companies: Personalis can drive growth by forging new partnerships with biopharmaceutical companies to integrate its NeXT platform into their drug development pipelines. The market for cancer therapies is projected to reach $200 billion by 2028, creating a significant opportunity for Personalis to capture a share of this market by providing genomic sequencing and data analysis services. Timeline: Ongoing.
- Increasing Adoption of Liquid Biopsy: The growing adoption of liquid biopsy for cancer diagnosis and monitoring presents a significant growth opportunity for Personalis. The liquid biopsy market is expected to reach $10 billion by 2027, driven by its non-invasive nature and ability to provide real-time insights into tumor dynamics. Personalis's NeXT Liquid Biopsy platform is well-positioned to capitalize on this trend. Timeline: Ongoing.
- Development of New Diagnostic Tests: Personalis can expand its product portfolio by developing new diagnostic tests based on its genomic sequencing and data analysis capabilities. The market for cancer diagnostic tests is projected to reach $30 billion by 2025, driven by the increasing demand for early and accurate cancer detection. Personalis's expertise in cancer genomics positions it favorably to develop innovative diagnostic solutions. Timeline: Ongoing.
- Geographic Expansion: Personalis can drive growth by expanding its geographic reach into new markets, particularly in Europe and Asia. The global cancer genomics market is expected to reach $50 billion by 2026, with significant growth potential in emerging markets. Personalis can leverage its existing technology and partnerships to establish a presence in these regions. Timeline: Ongoing.
- Data as a Service (DaaS) Offerings: Personalis can leverage its extensive genomic data to offer Data as a Service (DaaS) solutions to biopharmaceutical companies and research institutions. The market for DaaS in healthcare is projected to reach $15 billion by 2027, driven by the increasing demand for data-driven insights in drug development and clinical research. Personalis's genomic data and analytics capabilities position it favorably to capitalize on this trend. Timeline: Ongoing.
Opportunities
- Expanding partnerships with pharmaceutical companies.
- Increasing adoption of liquid biopsy for cancer diagnosis.
- Development of new diagnostic tests based on genomic sequencing.
- Geographic expansion into new markets.
Threats
- Intense competition in the cancer genomics market.
- Evolving regulatory landscape for genomic testing.
- Potential for technological obsolescence.
- Economic downturn impacting research funding.
Competitive Advantages
- Proprietary NeXT Platform: Offers comprehensive tumor and immune profiling.
- Extensive Genomic Data: Provides valuable insights for drug development.
- Strategic Partnerships: Collaborations with leading institutions like Mayo Clinic.
- Expertise in Cancer Genomics: Deep understanding of cancer biology and genomics.
About
Personalis, Inc., founded in 2011, is a cancer genomics company focused on transforming the development of cancer therapies through advanced genomic sequencing and data analysis. The company's core offering is the NeXT Platform, a comprehensive solution that provides detailed analysis of a tumor and its immune microenvironment from a single tissue or plasma sample. This platform enables biopharmaceutical companies, universities, non-profits, and government entities to gain deeper insights into cancer biology and accelerate the development of personalized cancer treatments. Personalis's product suite includes ImmunoID Next for tumor profiling from tissue, NeXT Liquid Biopsy for tumor profiling from plasma, NeXT Personal for personalized tumor tracking, NeXT Dx Test for genomic cancer profiling, and NeXT SHERPA and NeXT NEOPS for neoantigen prediction. The company also offers the ACE platform for clinical and therapeutic applications. Personalis has established strategic partnerships with leading institutions such as Mayo Clinic, MapKure, LLC, SpringWorks Therapeutics, Inc., and Moores Cancer Center, expanding its reach and impact in the cancer research and treatment landscape. Headquartered in Menlo Park, California, Personalis is committed to advancing the field of precision medicine and improving patient outcomes through innovative genomic solutions.
What They Do
- Provides sequencing and data analysis services for cancer therapies.
- Offers the NeXT Platform for tumor and immune microenvironment analysis.
- Develops ImmunoID Next for tumor profiling from tissue samples.
- Creates NeXT Liquid Biopsy for tumor profiling from plasma samples.
- Provides NeXT Personal for personalized tumor tracking.
- Offers NeXT Dx Test, a genomic cancer profiling test.
- Develops NeXT SHERPA and NeXT NEOPS for neoantigen prediction.
- Offers the ACE platform for clinical and therapeutic applications.
Business Model
- Provides genomic sequencing and data analysis services to biopharmaceutical companies.
- Generates revenue through sales of its NeXT Platform and related products.
- Partnerships with universities, non-profits, and government entities provide additional revenue streams.
- Offers data-as-a-service (DaaS) solutions based on its extensive genomic data.
Industry Context
Personalis operates within the medical diagnostics and research industry, a sector experiencing rapid growth driven by advancements in genomic sequencing and personalized medicine. The increasing demand for targeted cancer therapies and the growing adoption of liquid biopsies are fueling the expansion of the cancer genomics market. Personalis competes with companies like BFLY, CDNA, CSTL, EVH, and FLGT, all striving to provide innovative solutions for cancer research and treatment. The industry is characterized by intense competition, rapid technological advancements, and evolving regulatory landscapes. Personalis's NeXT platform and strategic partnerships position it favorably to capture a significant share of this expanding market.
Key Customers
- Biopharmaceutical companies developing cancer therapies.
- Universities conducting cancer research.
- Non-profit organizations focused on cancer treatment and prevention.
- Government entities involved in cancer research and healthcare.
Financials
Recent Quarterly Results
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q3 2025 | $14M | -$22M | $-0.24 |
| Q2 2025 | $17M | -$20M | $-0.23 |
| Q1 2025 | $21M | -$16M | $-0.18 |
| Q4 2024 | $17M | -$16M | $-0.23 |
Source: Company filings
Chart & Info
Price Chart
Personalis, Inc. (PSNL) stock price: $8.21 (+0.00, +0.00%)
Why Bull
- •Rumors of a potential partnership with a major player in personalized medicine are circulating, boosting confidence.
- •Recent insider buying activity suggests that those closest to the company believe in its future prospects.
- •The community is buzzing about Personalis's innovative approach to cancer treatment, seeing it as a potential game-changer.
- •There's a growing perception that the company is undervalued, with many believing it's poised for significant growth.
Why Bear
- •Competition in the personalized medicine space is intensifying, putting pressure on Personalis to maintain its edge.
- •Negative sentiment has emerged regarding recent changes in company leadership, creating uncertainty about its strategic direction.
- •Some community members express concern over the company's ability to scale its operations effectively to meet growing demand.
- •There's a perception that the market is overlooking potential regulatory hurdles that could impact Personalis's long-term prospects.
Latest News
-
AIGH Capital Dumps 2.6 Million Lumen Technologies Shares In $15.6 Million Exit
Motley Fool · Feb 3, 2026
-
Earnings Scheduled For November 4, 2025
benzinga · Nov 4, 2025
-
Earnings Scheduled For August 5, 2025
benzinga · Aug 5, 2025
-
Earnings Scheduled For May 6, 2025
benzinga · May 6, 2025
Technical Analysis
Rationale
AI-generated technical analysis for PSNL including trend direction, momentum, and pattern recognition.
What to Watch
Key support and resistance levels, volume signals, and upcoming events.
Risk Management
Position sizing, stop-loss levels, and risk-reward assessment.
Community
Discussion
Share your analysis and discuss Personalis, Inc. (PSNL) with other investors. Log in to post.
Sentiment
Community sentiment and discussion activity for PSNL.
Make a Prediction
Set your price target for Personalis, Inc. (PSNL), choose a timeframe, and track your prediction accuracy.
Current price: $8.21
Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for PSNL.
Price Targets
Wall Street price target analysis for PSNL.
Insider Flow (30d)
MoonshotScore
Score Factors
-
Revenue Growth 4/100
Revenue grew only 15.2% YoY, suggesting the company is in a slower growth phase.
-
Gross Margin 6/100
Gross margin of 26.7% is acceptable but leaves limited room for R&D and marketing investment.
-
Operating Leverage 4/100
Limited operating leverage due to slower revenue growth, keeping profit scaling constrained.
-
Cash Runway 6/100
Adequate cash of $91M covers near-term needs but may require additional funding for aggressive expansion.
-
R&D Intensity 10/100
Investing 57.8% of revenue in R&D signals heavy commitment to innovation and future product pipeline.
-
Insider Activity 6/100
No significant insider buying or selling recently, which is neutral for the stock outlook.
-
Short Interest 10/100
Daily turnover of 2.32% indicates healthy liquidity with smooth entry/exit for investors.
-
Price Momentum 3/100
Weak momentum with few bullish signals. The stock may be in a downtrend or consolidation phase.
-
News Sentiment 5/100
No sentiment data available
What does this score mean?
The MoonshotScore rates PSNL's growth potential on a scale of 0-100 across multiple factors including innovation, market disruption, financial health, and momentum.
Competitors & Peers
Frequently Asked Questions
What does Personalis, Inc. do?
Personalis, Inc. is a cancer genomics company that provides comprehensive genomic sequencing and data analysis services to biopharmaceutical companies, universities, and research institutions. The company's core offering is the NeXT Platform, which provides detailed analysis of a tumor and its immune microenvironment from a single tissue or plasma sample. This platform enables researchers and drug developers to gain deeper insights into cancer biology and accelerate the development of personalized cancer treatments. Personalis generates revenue through sales of its NeXT Platform and related products, as well as through partnerships with various organizations.
Is PSNL stock a good buy?
PSNL stock presents a mixed investment profile. The company operates in a high-growth sector with its NeXT platform offering a competitive advantage in cancer genomics. However, the negative P/E ratio of -9.67 and a profit margin of -106.9% raise concerns about profitability. The company's partnerships and innovative technology are positive indicators, but investors should carefully consider the financial risks and competitive landscape before investing. Monitoring the company's progress towards profitability and market share gains is crucial.
What are the main risks for PSNL?
Personalis faces several key risks. The company operates in a highly competitive market with established and emerging players, requiring continuous innovation to maintain its competitive edge. The evolving regulatory landscape for genomic testing could impact market access and reimbursement. The company's negative profit margin and high beta indicate financial and market volatility risks. Dependence on biopharmaceutical partnerships for revenue also poses a risk if these relationships are disrupted or terminated. Investors should carefully assess these risks before investing in PSNL.
Is PSNL a good stock to buy?
Whether PSNL is a good investment depends on your financial goals, risk tolerance, and investment horizon. Review the Investment Thesis, SWOT analysis, and Risk sections on this page. Always do your own research and consult a financial advisor before investing.
What is the PSNL MoonshotScore?
MoonshotScore is our proprietary AI-powered rating system that evaluates stocks based on growth potential, financial health, market momentum, and risk factors. It helps investors quickly identify high-potential opportunities. Check the MoonshotScore badge on this page for the current rating.
How often is PSNL data updated?
Stock prices are updated in real-time during market hours (9:30 AM - 4:00 PM ET). Company fundamentals, analyst ratings, and AI insights are refreshed daily. News is updated continuously throughout the day.
What are the growth catalysts for PSNL?
Growth catalysts vary by company and may include new product launches, market expansion, earnings surprises, partnerships, or industry tailwinds. Check the Catalysts section on this page for specific drivers relevant to Personalis, Inc..
Who are PSNL's main competitors?
Personalis, Inc.'s competitors depend on its industry and market segments. Check the Competitors section on this page for a list of direct competitors and how PSNL compares.
What do analysts say about PSNL?
Analyst ratings and price targets for PSNL are aggregated from multiple sources. Check the Analyst Consensus tab for buy/hold/sell ratings and the current consensus price target.
What is PSNL's market cap?
Market capitalization reflects the total market value of PSNL's outstanding shares. Check the Key Statistics section at the top of this page for the current market cap and other key financial metrics.
How has PSNL stock performed recently?
Check the Chart & Info tab for PSNL's recent price action, including daily, weekly, and monthly performance charts with technical indicators.
What are the risks of investing in PSNL?
Every stock carries risk. Check the Risks and Weaknesses sections on this page for PSNL-specific risk factors. Consider macroeconomic conditions, industry trends, and company-specific challenges.
Are insiders buying or selling PSNL?
Insider activity can signal management confidence. Check the Insider Flow tab for recent insider buys, sells, and exercise transactions for PSNL.
Is PSNL a good stock for beginners?
Personalis, Inc. (PSNL) can be suitable for beginner investors depending on several factors. Look at the MoonshotScore on this page for an overall AI-powered assessment of growth potential and risk. Beginners should also check the company's market cap (larger companies tend to be less volatile), gross margin (higher margins mean stronger business fundamentals), and cash position (healthy cash reduces bankruptcy risk). Always start with a small position size and never invest money you cannot afford to lose.
How risky is PSNL for first-time investors?
Every stock carries risk, including Personalis, Inc. (PSNL). First-time investors should review the Risk Factors section on this page for company-specific risks. Key risk indicators include price volatility (check the chart for daily swings), insider selling activity (see Insider Flow tab), and cash runway (see MoonshotScore breakdown). A diversified portfolio with an index fund like the S&P 500 as a core holding is generally recommended before adding individual stocks like PSNL.
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Data provided for informational purposes only.
- Financial data may be outdated.
- AI stock data is pending update.